Necrotizing Enterocolitis Market Trends Support A 6.1% CAGR Outlook Through The Forecast Period

The necrotizing enterocolitis (NEC) market is poised for notable expansion over the coming years, driven by significant advancements in neonatal care and treatment technologies. This growth reflects increasing investments and innovations aimed at improving outcomes for premature infants affected by this serious condition. Below, we explore the market size projections, key players, industry trends, and important segmentations shaping this sector.

Expected Market Size and Growth Trajectory for Necrotizing Enterocolitis
The market for necrotizing enterocolitis is forecasted to reach a valuation of $6.95 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period. This upward trend is primarily fueled by enhanced investments in neonatal intensive care units, breakthroughs in regenerative and stem cell therapies, heightened awareness around early detection of NEC, broader adoption of precision nutrition therapies, and advancements in neonatal imaging technologies. Key trends influencing the market include increased use of probiotics and prebiotics to prevent NEC, greater emphasis on early diagnosis and screening of premature infants, rising use of personalized total parenteral nutrition (TPN) solutions, expansion of minimally invasive surgical techniques, and improvements in neonatal critical care and monitoring systems.

The necrotizing enterocolitis market size has grown strongly in recent years. It will grow from $5.14 billion in 2025 to $5.47 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to high incidence of premature births, limited neonatal care infrastructure, reliance on broad-spectrum antibiotics, delayed diagnosis in low-resource settings, early development of parenteral nutrition.

Download a free sample of the necrotizing enterocolitis market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Making an Impact in the Necrotizing Enterocolitis Market
Several prominent players are actively contributing to the development and commercialization of NEC-related treatments and solutions. These include Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children's Hospital, Hollister Incorporated, UPMC Children's Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., and Chosen Diagnostics Inc.

A Noteworthy Partnership Advancing NEC Research
In January 2025, Siolta Therapeutics, a US-based company developing innovative live biotherapeutics for NEC, entered into a partnership with Cowellnex Co. This collaboration is intended to prevent necrotizing enterocolitis in premature infants by combining Siolta's expertise in microbial science with Cowellnex's robust institutional capabilities. By leveraging Siolta's Precision Symbiotics Platform, the alliance aims to enhance microbiome drug discovery and advance therapeutic development. Cowellnex Co. Ltd. is a biotechnology firm based in the US that specializes in microbiome drug innovation.

View the full necrotizing enterocolitis market report:
https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Shaping Innovation in Necrotizing Enterocolitis Treatment
Industry leaders are focusing on novel solutions such as cell-free sterile biologic products designed to meet critical unmet needs in NEC therapy and improve clinical outcomes for vulnerable premature infants. These biologics consist of purified, sterile liquids containing bioactive molecules like proteins, growth factors, and cytokines, derived from cultured cells but without any whole cells, intended to promote healing and reduce inflammation.

A significant milestone in these efforts occurred in December 2023 when Noveome Biotherapeutics, a US biopharmaceutical company, received FDA clearance to proceed with a Phase 1-2 clinical trial of ST266. This innovative biologic aims to treat necrotizing enterocolitis in premature infants and represents the first major therapeutic advancement for NEC in over three decades. Given the disease's high morbidity and mortality rates, ST266 holds promise as a critical breakthrough in pediatric care.

Segment-Wise Breakdown and Comparative Overview of the Necrotizing Enterocolitis Market
The necrotizing enterocolitis market is categorized into several key segments to better understand the scope and application of treatments:

1) Treatment Types:
- Total Parenteral Nutrition (TPN)
- Gastrointestinal Decompression
- Antimicrobial Therapy
- Antifungal Treatment
- Paracentesis
- Other Treatments

2) Diagnostic Methods:
- Laboratory Tests
- Imaging Techniques

3) Disease Stages:
- Stage I (Suspected NEC)
- Stage II (Definite NEC)
- Stage III (Advanced NEC)

4) End-User Settings:
- Hospitals
- Neonatal Intensive Care Units (NICUs)
- Specialty Clinics

Further subdivisions include:

By TPN: standard formulations, customized or individualized TPN solutions, lipid emulsions, protein and amino acid supplements, and micronutrient- and electrolyte-enhanced formulations.

By Gastrointestinal Decompression: nasogastric and orogastric tube decompression, surgical gastrostomy, and non-surgical decompression techniques.

By Antimicrobial Therapy: broad-spectrum antibiotics, gram-positive and gram-negative coverage antibiotics, combination therapies, and prophylactic antibiotic use for high-risk neonates.

By Antifungal Treatment: systemic antifungal therapies, prophylactic antifungal use in preterm infants, and combination antifungal-antibiotic regimens for severe NEC cases.

By Paracentesis: diagnostic, therapeutic, and ultrasound- or radiology-guided procedures.

By Other Treatments: use of probiotics and prebiotics for NEC prevention, surgical interventions, stem cell and regenerative medicine approaches, immunomodulatory therapies, and supportive care.

These diverse segments reflect the multifaceted strategies employed to manage and treat necrotizing enterocolitis while catering to varying patient needs and clinical settings.

New analytical features added to our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.